Guidelines and Recommendations


The below links to evidence-based clinical guidelines and recommendations provide guidance on the use of emicizumab in patients with hemophilia A.

National Bleeding Disorders Foundation Medical and Scientific Advisory Council (MASAC Document #268)

Recommendations on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors.

National Bleeding Disorders Foundation Medical and Scientific Advisory Council (MASAC Document #267)

Recommendations on prophylaxis for hemophilia A and B with and without inhibitors.

World Federation of Hemophilia Guidelines for the Management of Hemophilia, 3rd edition

Srivastava A, Santagostino E, Dougall  A, et al.  Haemophilia. 2020;26 Suppl 6:1-158.